# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home pri...
JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $...
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance r...
72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract; Rapid and sustained improveme...
Raymond James analyst Steven Seedhouse maintains Vera Therapeutics (NASDAQ:VERA) with a Strong Buy and raises the price targ...
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(0.56) per share. This is a 30 percent increase over losses of $(...
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-media...